JLL Japan Lifeline : Summary Report of Consolidated Financial Results for the Nine Months Ended December 31, 2017 (125KB)

Summary Report of Consolidated Financial Results for the Nine Months Ended December 31, 2017 [Japan GAAP]

January 31, 2018

Company name:	Japan Lifeline Co., Ltd.
Code No.:	7575
Listed Stock Exchange:	Tokyo Stock Exchange, 1st Section
URL:	http://www.jll.co.jp/
Representative:	Keisuke Suzuki, President and CEO
Contact person:	Shogo Takahashi, Executive Vice President Corporate Administration Department
TEL:	[phone]

Scheduled date for filing the Quarterly Securities Report: February 14, 2018

Dividend payable date: -

Supplementary material to the quarterly financial statements: None Presentation on quarterly results: None

（Notes: Amounts are rounded down to million yen）

1. Consolidated Results for the Nine Months Ended December 31, 2017 (from April 1, 2017 to December 31, 2017)

(1) Consolidated operating results

(Notes: % represent year-on-year changes)

Net sales	Operating income	Ordinary income	Net income
Nine months ended December 31, 2017 Nine months ended December 31, 2016	Millions of yen % 31,152 14.3 27,264 25.6	Millions of yen % 7,718 41.9 5,440 112.0	Millions of yen % 7,873 37.2 5,737 123.6	Millions of yen % 5,367 40.8 3,813 76.8

(Note) Comprehensive income : Nine months ended December 31, 2017 : 5,402 million yen ( 45.1% )

Nine months ended December 31, 2016 : 3,724 million yen ( 72.7% )

Earnings per share	Diluted earnings per share
Nine months ended December 31, 2017 Nine months ended December 31, 2016	Yen 72.13 51.24	Yen 72.06 -

(Note) The Company conducted a two-for-one stock split of its common stock, with an effective date of December 1, 2016 and conducted another two-for-one stock split of its common stock, with an effective date of January 1, 2018. Earnings per share and diluted earnings per share are calculated by deeming stock splits to have occurred at the beginning of the previous consolidated fiscal year.

(2) Consolidated financial position

Total assets	Net assets	Equity ratio
As of December 31, 2017 As of March 31, 2017	Millions of yen 44,241 40,427	Millions of yen 25,091 20,750	% 56.6 51.3

(Reference) Shareholders' equity : Nine months ended December 31, 2017 : 25,036 million yen

Year ended March 31, 2017

: 20,750 million yen

2. Dividends

Cash dividends per share
1Q End	2Q End	3Q End	Year-End	Total
Year ended March 2017 Year ending March 2018	Yen - -	Yen 0.00 0.00	Yen - -	Yen 30.00	Yen 30.00
Year ending March 2018 (forecast)	-	28.75	28.75

(Notes) 1 Revisions from the recent dividends forecast: Yes

2 The Company conducted a two-for-one stock split of its common stock, with an effective date of January 1, 2018. The fiscal year-end dividend amount for year ended March 31, 2017 reflects the result before this stock split.

3. Forecast of Consolidated Results for the Year Ending March 31, 2018 (from April 1, 2017 to March 31, 2018)

(Notes: % represents change from the previous year)

Net sales	Operating income	Ordinary income	Net income	Earnings per share
Year ending March 31, 2018	Millions of yen % 42,466 14.2	Millions of yen % 10,664 38.8	Millions of yen % 10,908 36.2	Millions of yen % 7,480 39.8	Yen 98.53

(Note) 1 Revisions from the recent earnings forecast: Yes

2 The Company conducted a two-for-one stock split of its common stock, with an effective date of January 1, 2018.

Earnings per share are calculated by deeming stock splits to have occurred at the beginning of this consolidated fiscal year.

* Notes

(1) Changes in significant subsidiaries during the period : Yes

Exclusion : 1 (JUNKEN MEDICAL Co., Ltd.)

(2)Application of special accounting methods for the preparation of the consolidated quarterly financial statement : None

• (3) Changes in accounting policies, accounting estimates and restatement

  ( i ) Changes in accounting policies associated with revision of accounting standards : None

  (ii ) Changes in accounting policies other than ( i )

  • : None

    • (iii) Changes in accounting estimates

  • : None

    • (iv) Restatement

  • : None

• (4) Number of common shares issued (common stock)

  ( i ) Number of issued shares as of the period-end (including treasury stock):

Nine months ended December 31, 2017 : 90,419,976 shares Year ended March 31, 2017 : 90,419,976 shares

(ii ) Number of treasury stock shares as of the period-end:

Nine months ended December 31, 2017 : 16,005,616 shares Year ended March 31, 2017 : 16,005,616 shares

(iii) Average number of common shares during the period (quarterly cumulative total):

Nine months ended December 31, 2017 : 74,414,360 shares

Nine months ended December 31, 2016 : 74,414,360 shares

(Note) 1 The Company conducted a two-for-one stock split of its common stock, with an effective date of December 1, 2016 and conducted another two-for-one stock split of its common stock, with an effective date of January 1, 2018.

"(4) Number of common shares issued (common stock)" is calculated by deeming stock splits to have occurred at the beginning of the previous consolidated fiscal year.

2 The Company has introduced a BIP (Board Incentive Plan) trust, and the number of shares of the Company owned by the trust are included in "(4) Number of common shares issued (common stock) ".

* This quarterly Summary Report is not subject to the quarterly audit.

* Explanation regarding appropriate use of business forecasts, and other special instructions

Any forward-looking statements in the report, including results forecasts, are based on information currently available to the Company and certain assumptions that the Company deems to be reasonable at the time this report was prepared. Actual results may differ significantly from the forecasts due to various factors.